Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioXcel To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - July 6, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI).
If you suffered losses exceeding $50,000 investing in BioXcel stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BTAI.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
On June 29, 2023, BioXcel disclosed in a regulatory filing its Phase 3 trial for Alzheimer's successfully achieved its primary objective; however, investor concerns arose due to a principal investigator's timeliness in reporting a serious adverse event. Along with this, the FDA uncovered a non-compliance issue at the site where the principal investigator enrolled around 40% of the participants in the study, known as TRANQUILITY II.
Following this news, BioXcel stock dropped 56% during premarket trading on June 29, 2023.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/172602
Original Source of the original story >> BioXcel Investor Alert
